IBD is an innovative SME, a biomedical devices manufacturer company conceived in London and founded in Italy in 2014.
Guided by a team with +10 years of experience in medical device design, IBD has raised so far over € 1 million in funding from angel investors and grants.
It is now facing a new round of funding.
IBD looks at reverse innovation of biomedical devices as key to make quality healthcare affordable for the most.
Our mission is to solve healthcare issues through the application of the reverse innovation principles.
We investigate the existent technological limitations that are part of the problem to create the best medical device in terms of efficiency, optimization of costs, and usability.
Partnership with SECO Group for the industralization of BioRespira
Partnership with SECO GROUP, a leading company in the hi-tech sector, specializing in computer miniaturization, backed by FII Tech Growth managed by Fondo Italiano d’Investimento SGR, for the industrialization of BioRespira.
#LETTHEMBREATHE crowdfunding campaign
IBD launched a successful crowdfunding campaign, named #LETTHEMBREATHE, to support the development activities of Respira.
Development of BioRespira
During the COVID-19 pandemic, in an attempt to help alleviate emergency and shocked by the scarce presence of ventilator manufacturers in Italy, the team decided to develop a ventilator for sub-intensive therapy with high flow and mixing of oxygen.
The final product MyDial was tested at the identified accredited laboratory. IBD obtained the EC Quality Assurance System Certificate by KIWA Italy.
Manifold and the bloodline disposable were validated, through the operational simulation of an entire dialysis treatment.
Seal of Excellence Horizon 2020
Certificate 854722 delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020.
POR FESR call for innovative Startups
IBD obtained non-repayable loan of 100k€ from the Emilia-Romagna Region.
Third Prototype Tested and Validated
The third protype of MyDial has been tested and validated in vitro.
IBD prototyped the Manifold, improved the ultrafiltration control and started activities to obtain the CE certification of Dial-IT
The first prototype of MyDial was developed using a PC-controlled data acquisition platform.
The MyDial technological concept has been formulated.
In May 2014 Corrado Ghidini and Andrea Visotti founded the Start up IBD Srl and opened an R&D laboratory in Bologna (Italy).
In compliance with the Italian Ministry of Health’s provisions regarding health advertising relating to medical devices, in vitro diagnostic medical devices and medical-surgical devices, IBD informs that the contents of this site are intended exclusively for healthcare professionals. The description of the products is for information purposes only and is not intended to promote them.